iSpecimen (NASDAQ:ISPC – Get Rating) is one of 44 publicly-traded companies in the “Commercial physical research” industry, but how does it compare to its rivals? We will compare iSpecimen to related businesses based on the strength of its valuation, analyst recommendations, institutional ownership, earnings, profitability, dividends and risk.
Analyst Ratings
This is a summary of recent ratings and target prices for iSpecimen and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| iSpecimen | 0 | 0 | 1 | 0 | 3.00 |
| iSpecimen Competitors | 48 | 715 | 1292 | 27 | 2.62 |
iSpecimen presently has a consensus target price of $7.63, indicating a potential upside of 510.00%. As a group, “Commercial physical research” companies have a potential upside of 34.59%. Given iSpecimen’s stronger consensus rating and higher probable upside, analysts clearly believe iSpecimen is more favorable than its rivals.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| iSpecimen | -98.50% | -42.83% | -35.26% |
| iSpecimen Competitors | -240.85% | -12.53% | -7.46% |
Institutional & Insider Ownership
11.6% of iSpecimen shares are owned by institutional investors. Comparatively, 52.5% of shares of all “Commercial physical research” companies are owned by institutional investors. 32.3% of iSpecimen shares are owned by insiders. Comparatively, 13.4% of shares of all “Commercial physical research” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares iSpecimen and its rivals gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| iSpecimen | $10.40 million | -$10.25 million | -1.08 |
| iSpecimen Competitors | $1.63 billion | $77.00 million | 3.63 |
iSpecimen’s rivals have higher revenue and earnings than iSpecimen. iSpecimen is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
iSpecimen has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500. Comparatively, iSpecimen’s rivals have a beta of 4.87, indicating that their average stock price is 387% more volatile than the S&P 500.
Summary
iSpecimen rivals beat iSpecimen on 8 of the 13 factors compared.
About iSpecimen
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for iSpecimen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iSpecimen and related companies with MarketBeat.com's FREE daily email newsletter.
